Form 4: Boston Scientific Director Sells 4,000 Shares Under Pre-Arranged Trading Plan

Edward J. Ludwig, a Director at Boston Scientific Corp (BSX), sold 4,000 shares of common stock for approximately $418,367 under a Rule 10b5-1 trading plan.

Summary

• Edward J. Ludwig, a Director of Boston Scientific Corp (BSX), reported the sale of 4,000 shares of the company's common stock.
• The transaction occurred on May 29, 2025, at a weighted average sale price of $104.5919 per share.
• The shares were sold in multiple transactions with prices ranging from $104.59 to $104.615, inclusive.
• This sale was conducted pursuant to a Rule 10b5-1(c) trading plan, indicating it was a pre-arranged transaction.
• Following this transaction, Mr. Ludwig directly beneficially owns 22,479 shares of Boston Scientific common stock.

Sentiment

Score: 5

Explanation: The sentiment is neutral. While it's an insider sale, the disclosure that it was made under a Rule 10b5-1 plan mitigates any negative signal, as it indicates a pre-scheduled transaction rather than a reaction to new, negative information.

Negatives

• The sale of shares by a director reduces their direct ownership stake in the company, which can sometimes be perceived as a lack of confidence, although mitigated by the 10b5-1 plan.

Risks

• While the sale was pre-arranged under a 10b5-1 plan, significant or repeated insider selling, even under such plans, could potentially be interpreted negatively by the market, impacting investor sentiment.

Future Outlook

The document is a Form 4 filing disclosing an insider transaction and does not contain any forward-looking statements or guidance regarding the company's future outlook.

Industry Context

This Form 4 filing pertains to an individual director's stock transaction and does not provide broader insights into Boston Scientific's position within the medical device industry or its competitive landscape. It is a routine disclosure of insider activity.

Stakeholder Impact

• Shareholders: The sale by a director, even if pre-arranged, slightly reduces insider alignment, but the impact is minimal given the small volume relative to the company's market capitalization and the pre-scheduled nature of the sale.

Key Dates

Keywords

Boston Scientific, BSX, Form 4, Insider Trading, Stock Sale, Director, Edward J. Ludwig, SEC Filing, Medical Devices